Navigation Links
Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:12/2/2009

court judgment finding the patents invalid or not infringed or 30 months from the company's October 2009 receipt of a Paragraph IV certification letter from Teva.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL (armodafinil) Tablets [C-IV], TREANDA® (bendamustine hydrochloride) for Injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride), PROVIGIL® (modafinil) Tablets [C-IV] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
2. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
3. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
4. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
5. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
6. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
9. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
10. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
11. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Pulmonary Fibrosis Foundation (PFF) and Veracyte, ... the organizations are partnering on a U.S. patient ... with interstitial lung diseases (ILDs), including idiopathic pulmonary ... (INTENSITY) survey will assess the steps and time ...
(Date:8/27/2015)... 27, 2015  QB3@953—a San Francisco ... of California (UC) research institute and biotech accelerator— ... to identify and facilitate collaborations to translate early ... The agreement formalizes a relationship between ... team and creates a new channel for DPAc ...
(Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. 27, ... presenting at the Rodman & Renshaw 17th Annual Global Investment ... at the St. Regis Hotel, ORYZON will be represented by ... Dr. Buesa will present this ... at the Fontainebleau Room (2nd Floor).  The company is completing ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... EAST SETAUKET, N.Y., Dec. 19, 2011  An article in the ... of the National Academy of Sciences USA , reported ... therapeutic potential in a laboratory model of Gaucher disease  ... and president of Lixte said, "This is a novel ...
... MISSISSAUGA, Ontario, Dec. 19, 2011  Valeant Pharmaceuticals International, ... VRX) announced that effective December 16, 2011, the ... a dermatology unit of Sanofi (EURONEXT: SAN and ... International, Inc. Valeant Pharmaceuticals International, ...
Cached Medicine Technology:Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 2Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 3
(Date:8/27/2015)... ... August 27, 2015 , ... ... with Julia Glushko, professional Tennis player for Israel in the Women’s Tennis Association ... for all her training and recovery. , With a focus on technology and ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of ... third doctoral program at its main campus in Reading: Doctor of Nursing Practice. , ... to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... partnership agreement for quality market research promotion on the Internet. MarketPublishers.com is ... Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager at ...
(Date:8/27/2015)... TX (PRWEB) , ... August 27, 2015 , ... ... cutting edge procedure to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and ... using a CO2 laser, which delivers controlled energy to the vaginal tissue, revitalizing cells ...
Breaking Medicine News(10 mins):Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3
... Sept. 8 , , WHAT: ... growing radio shows-- The CEO Show-- draws a clever analogy ... upcoming Webinar taken from his book titled, Golf and the Art ... the research and educational arm of Beryl, the nation,s leading healthcare-exclusive call ...
... , , , ... Health Integrated, a leading provider of Health Management Solutions, has ... the health plan integrates the management of behavioral health benefits ... solution, Health Integrated will provide Blue Cross of Idaho with ...
... , Nurses to March for Employee ... in Single-Payer Systems , , SAN ... the largest union and professional association of nurses in U.S. history, ... the biennial convention of California,s largest RN organization, the California Nurses ...
... , , LOS ANGELES, Sept. 8 ... obesity epidemic and a general lack of healthy living. In his new ... Help of a Personal Trainer" ( published by AuthorHouse ), ... lost over 60 pounds with the help of a personal trainer, and ...
... , LONDON, Sept. 8 The 2009 Frost ... Risk Management Award is presented to Pronova BioPharma ASA. The ... FDA-approved omega-3 derived prescription drug. Branded Omacor in Europe ... a prescribed adjunct to diet for the treatment of elevated ...
... , WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ ... health care reform, a new analysis by the Center for ... receive benefits under the House health reform bill (H.R. 3200). ... for the new taxpayer-funded affordability credits, there is nothing in ...
Cached Medicine News:Health News:The Beryl Institute Sponsors Free Customer Service Webinar with Robert Reiss 2Health News:Health Integrated Enters into Agreement with Blue Cross of Idaho to 'Carve-in' Behavioral Health Management 2Health News:1,200 RNs Gather in San Francisco Tuesday: Take Next Step to Form Nation's Largest Ever Union of Nurses 2Health News:The Simple ABCs of Weight Loss and Fitness 2Health News:The Simple ABCs of Weight Loss and Fitness 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 2Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 4Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 5Health News:Health Bill Could Benefit 6.6 Million Illegals 2Health News:Health Bill Could Benefit 6.6 Million Illegals 3
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
4 mm blade. Flat handle....
9 mm button end blade. 15 mm long backcutting blade. Angled at 45 degrees. Flat handle. Designated most popular model or size....
10 mm blade, angled left. Flat handle....
Medicine Products: